| 0.1 -0.006 (-5.66%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.17 | 1-year : | 0.2 |
| Resists | First : | 0.14 | Second : | 0.17 |
| Pivot price | 0.1 |
|||
| Supports | First : | 0.09 | Second : | 0.07 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.11 |
| MA(100) : | 0.3 |
MA(250) : | 2.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 13.8 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 10.81 | Low : | 0.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PPCB ] has closed above bottom band by 22.3%. Bollinger Bands are 82.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 160 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.11 - 0.11 | 0.11 - 0.11 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.1 - 0.1 | 0.1 - 0.1 |
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Mon, 20 Apr 2026
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Fri, 17 Apr 2026
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB - Business Wire
Tue, 24 Mar 2026
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - Yahoo Finance
Tue, 10 Mar 2026
Propanc Biopharma signs contract for Phase 1b cancer trial assay - Investing.com
Thu, 05 Feb 2026
Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.083e+007 (%) |
| Held by Institutions | 40.4 (%) |
| Shares Short | 249 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.51e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -535.8 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 229.94 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 52.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.45 |
| Dividend | 0 |
| Forward Dividend | 143590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|